The performance of RefluxStop surgery at University Hospital Southampton follows its use at St Mary’s Hospital in 2023.
Medtech Implantica’s RefluxStop device for gastro-oesophageal reflux disease (GORD) has been rolled out at University Hospital Southampton.
The Swedish company’s device was first used in the National Health Service (NHS) in September of last year at St Mary’s Hospital, part of Imperial College Healthcare NHS trust.
Until now, proton pump inhibitors (PPIs), a class of drugs that reduce the amount of stomach acid produced by the glands in the stomach lining, have been a common method in addressing GORD. However, according to Implantica CEO Peter Forsell, up to 40% of patients are not helped by PPIs. In addition, studies have shown that PPI use can increase the risk of gastric cancer.
Forsell states that in the US and Europe combined, around 48,000 people die from oesophageal cancer each year.
Comments are closed.